Please login to the form below

Not currently logged in


This page shows the latest CTCL news and features for those working in and with pharma, biotech and healthcare.

New leader at Medivir after setbacks

New leader at Medivir after setbacks

lead compound remetinostat, intended as a treatment for early-stage cutaneous T-cell lymphoma (CTCL), because it couldn’t agree on a design with the FDA. ... Medivir bought the rights to remetinostat from TetraLogic Pharma for $12m upfront in November

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    30600. Therakos. Mallinckrodt. Approved cell therapy platform for the palliative treatment of cutaneous T‐cell lymphoma [CTCL].

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    387. Ceptaris Therapeutics / Actelion. Acquisition. Valchlor for mycosis fungoides-type CTCL (NDA). ... CTCL = cutaneous T-cell lymphoma. VLP  = virus-like particle produced in plant expression systems .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....